Login to Your Account



Clinic Roundup


Tuesday, June 12, 2012
• BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., said that it will embark on two new Phase III efficacy trials of LibiGel, a testosterone therapy for female sexual dysfunction, and that it will continue ongoing LibiGel Phase III cardiovascular and breast cancer safety studies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription